News and Announcements
SUDA June 2016 Investor Update; Negotiations to Licence Oro-Muscal Sprays Continue, Expansion of Business Development in China, ChinaBio Conference
- Published June 07, 2016 3:57PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
7th June 2016, ASX Announcement
SUDA Ltd (ASX: SUD), a leader in oro-muscal drug delivery, notes the weakness in its share price and today provides an update on its activities. Negotiations with pharmaceutical companies to licence SUDA’s first-in-class oro-muscal sprays continue to advance towards final agreements. These discussions span various products and territories. Subject to successful contract negations, SUDA could finalise several agreements in the next few weeks and months.
SUDA has recently expanded its business development outreach in China and met with over 20 Chinese pharmaceutical companies at the ChinaBio conference in Suzhou on 18-19 May 2016. Some of these meetings have already advanced to full due diligence and discussions of terms.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
